You may be a little unfamiliar with immunotherapy for it is relatively new in biotech field, but it has been commercially successful. Immunotherapeutics in the market include inhibitors like Humira (adalimumab; AbbVie Inc.), for autoimmune diseases such as plaque psoriasis, rheumatoid arthritis, and ulcerative colitis, and Erbitux (cetuximab; Eli Lilly and Co.), for head-and-neck and metastatic colon cancer. There are also some other big companies in the trial, such as Bristol-Myers Squibb Co. and Genentech/Roche Holding AG, developer of blockbusters Avastin (bevacizumab) and Rituxan (rituximab).
These therapies have shown great efficacy in treating various diseases either on the cell membrane or in the microenvironment surrounding. But sector analysts and researchers consider the interior of the cell the ultimate target—or, as Frost & Sullivan analyst Dorman Followwill dubs it, the "Holy Grail" of cancer treatment. They want to deal with cancer by taking out the core of it. At that time, nothing is left and cancer is cured.
Recently, Inovio Pharmaceuticals Inc. and Sorrento Therapeutics Inc. have launched a new collaboration focused on delivering therapeutics intracellularly. For the last 30 years, scientists have always been seeking ways of building inside the cell. Here come more breakthroughs.
没有评论:
发表评论